---
title: "Urine cfDNA methylation distinguishes non‑muscle invasive bladder cancer: pilot cfMeDIP‑seq study"
id: "medrxiv-22-urine-dna-methylation-as-a-potential-diagnostic-and-surveillance-tool-in-non"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-urine-dna-methylation-as-a-potential-diagnostic-and-surveillance-tool-in-non"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.18.26363402v1?rss=1"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Urine cfDNA methylation distinguishes non‑muscle invasive bladder cancer: pilot cfMeDIP‑seq study
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-urine-dna-methylation-as-a-potential-diagnostic-and-surveillance-tool-in-non
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.18.26363402v1?rss=1)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This pilot study evaluated **urine cell‑free DNA (cfDNA) methylation** as a noninvasive diagnostic and surveillance approach for **non‑muscle invasive bladder cancer (NMIBC)** in a Thai cohort. - Five patients with high‑grade NMIBC and three healthy volunteers provided midstream urine and blood samples collected prior to transurethral resection of bladder tumor (TUR‑BT). - Urine cfDNA was extracted, enriched for fragment sizes by mechanical shearing (from ~400 bp to 150–200 bp), and profiled using cell‑free methylated DNA immunoprecipitation followed by high‑throughput sequencing (**cfMeDIP‑seq**). - Differentially methylated regions (DMRs) were identified between NMIBC samples and controls with statistical adjustment; initial analysis found 82 DMRs (76 hypermethylated, 6 hypomethylated) at adjusted P < 0.001. - Top hypermethylated loci in the initial analysis included **IRX4**, **TBX5**, and **MIR124‑3**. - A refined analysis excluding two outlier samples (labelled UC2 and UC3) increased signal with 476 significant DMRs (449 hypermethylated), and principal component analysis (PCA) showed clear segregation of NMIBC versus controls. - In the refined set the most significantly hypermethylated targets were **MIR124‑3**, **IRX4**, and **LHX1‑DT**, proposed as demographic‑specific biomarker candidates. - The study asserts that cfMeDIP‑seq bypasses limitations of bisulfite conversion for degraded urine DNA and provides a technically validated foundation for urine methylation‑based surveillance and diagnostics. - The authors state ethical approval (IRB No. RA64/053), informed consent, and registration in the Thai Clinical Trials Registry (TCTR20210813003). - Data availability: raw cfMeDIP‑seq datasets have been deposited in the NCBI Sequence Read Archive and will be provided upon manuscript acceptance; other clinical and baseline data are included in the manuscript and supporting files. - Limitations implicit in the report include the small sample size and the presence of cohort heterogeneity reflected by two outlier urine samples; the manuscript is a preprint and has not been peer reviewed.
## Clinical Analysis & Structured Key Points
Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study | medRxiv Skip to main content Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study Thongtra Watcharawitayakul , Julin Ophanurak , Dutsadee Sowanthip , Poorichaya Somparn , Trairak Pisitkun , View ORCID Profile Panot Sainamthip doi: https://doi.org/10.64898/2026.09.18.26363402 Thongtra Watcharawitayakul Chulalongkorn University Faculty of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Julin Ophanurak Chulalongkorn University Faculty of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dutsadee Sowanthip Chulalongkorn University Faculty of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Poorichaya Somparn Chulalongkorn University Faculty of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Trairak Pisitkun Chulalongkorn University Faculty of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Panot Sainamthip Chulalongkorn University Faculty of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Panot Sainamthip For correspondence: panot.s{at}chula.ac.th Abstract Info/History Metrics Data/Code Preview PDF Abstract Non-muscle invasive bladder cancer (NMIBC) exhibits high recurrence, necessitating frequent invasive surveillance. Urine DNA methylation profiling represents a promising non-invasive biomarker approach for early detection and monitoring. This pilot study aimed to investigate urine DNA methylation patterns in NMIBC among Thai patients. Five patients with high-grade NMIBC and three healthy volunteers were enrolled, and midstream urine and blood samples were collected prior to transurethral resection of bladder tumor (TUR-BT). Urine cell-free DNA (cfDNA) was extracted, mechanically sheared from an atypical peak of approximately 400 bp to an optimal target length of 150–200 bp, and analyzed using cell-free methylated DNA immunoprecipitation followed by high-throughput sequencing (cfMeDIP-seq). Differentially methylated regions (DMRs) were identified between NMIBC and controls, and principal component analysis (PCA) was performed. A total of 82 DMRs were identified (adjusted P < 0.001), including 76 hypermethylated and 6 hypomethylated regions, with IRX4, TBX5, and MIR124-3 representing the top hypermethylated genes. To account for cohort heterogeneity, a refined subset analysis excluding two outlier samples (UC2 and UC3) was performed, revealing 476 significant DMRs (449 hypermethylated). PCA demonstrated clear, robust segregation between NMIBC and controls, highlighting MIR124-3, IRX4, and LHX1-DT as the most significantly hypermethylated targets. Our findings demonstrate that urine cfDNA methylation profiling can robustly distinguish NMIBC from healthy controls, highlighting MIR124-3, IRX4, and LHX1-DT as highly promising, demographic-specific biomarkers. This non-invasive approach successfully bypasses the degradative limits of traditional bisulfite conversion and establishes a technically validated foundation for clinical surveillance and diagnostics Competing Interest Statement The authors have declared no competing interest. Clinical Trial The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (Approval No. IRB No.RA64/053). All participants gave informed written consent for study participation prior to inclusion. This study was registered with Thai Clinical Trials Registry number TCTR20210813003. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (Approval No. IRB No.RA64/053). All participants gave informed written consent for study participation prior to inclusion. This study was registered with Thai Clinical Trials Registry number TCTR20210813003. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The raw sequencing datasets (cfMeDIP-seq) generated and analyzed during the current study have been deposited in the NCBI Sequence Read Archive (SRA) and will be provided upon manuscript acceptance. All other minimal clinical and baseline demographic data necessary to replicate the findings are included within the manuscript and its Supporting Information files. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study Thongtra Watcharawitayakul , Julin Ophanurak , Dutsadee Sowanthip , Poorichaya Somparn , Trairak Pisitkun , Panot Sainamthip medRxiv 2026.09.18.26363402; doi: https://doi.org/10.64898/2026.09.18.26363402 Share This Article: Copy Citation Tools Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study Thongtra Watcharawitayakul , Julin Ophanurak , Dutsadee Sowanthip , Poorichaya Somparn , Trairak Pisitkun , Panot Sainamthip medRxiv 2026.09.18.26363402; doi: https://doi.org/10.64898/2026.09.18.26363402 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Oncology Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4832) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15979) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7067) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5060) Health Policy (1438) Health Systems and Quality Improvement (1775) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16309) Intensive Care and Critical Care Medicine (1175) Medical Education (671) Medical Ethics (155) Nephrology (727) Neurology (7294) Nursing (368) Nutrition (1084) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1006) Oncology (3616) Ophthalmology (1055) Orthopedics (398) Otolaryngology (458) Pain Medicine (474) Palliative Medicine (139) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (768) Psychiatry and Clinical Psychology (5921) Public and Global Health (9772) Radiology and Imaging (2433) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (581) Surgery (782) Toxicology (107) Transplantation (305) Urology (293)
## Related Clinical Research

- [Scalable Causal-Interpretable ML for Cancer Prescreening from Electronic Health Records](https://medichelpline.com/clinical-feed/medrxiv-15-scalable-causal-interpretable-machine-learning-for-cancer-prescreening-using.md)
- [Genome-wide genetic dataset generated for the Australian 45 and Up Study](https://medichelpline.com/clinical-feed/medrxiv-17-a-genome-wide-genetic-data-resource-for-the-45-and-up-study.md)
- [Integrative oncology works for cancer symptoms — insurers lag on coverage](https://medichelpline.com/clinical-feed/stat-news-4-opinion-the-science-on-relieving-cancer-symptoms-is-clear-why-isn-t-insurance.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Inflammatory Biomarkers and Risk of Postmenopausal ER-Positive Breast Cancer](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-receptor-positive.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.